Table 1. Patient characteristics at time of metastases diagnosis (n = 379).
| Characteristics | No. | % |
|---|---|---|
| Median age (years, range) | 49 (25–76) | |
| <40 | 73 | 19.3 |
| ≥40 | 306 | 80.7 |
| Pathological types | ||
| Invasive ductal carcinoma | 355 | 93.7 |
| Others | 24 | 6.3 |
| Menstruation status | ||
| Pre- or peri-menopausal | 179 | 47.2 |
| Post-menopausal | 200 | 52.8 |
| ECOG performance status | ||
| 0 | 87 | 23.0 |
| 1 | 281 | 74.1 |
| ≥2 | 11 | 2.9 |
| Time between breast surgery and recurrent disease(months, range) | 14.3 (0–217.0) | |
| <12 | 133 | 35.1 |
| ≥12 | 224 | 59.1 |
| de novo metastatic | 22 | 5.8 |
| Number of metastatic organ sites | ||
| 1 | 126 | 33.2 |
| 2 | 143 | 37.7 |
| ≥ 3 | 110 | 29.0 |
| Metastatic sites | ||
| Lymph node | 230 | 60.7 |
| Lung | 163 | 43.0 |
| Chest wall | 108 | 28.5 |
| Bone | 99 | 26.1 |
| Liver | 76 | 20.1 |
| Pleura | 32 | 8.4 |
| Brain | 11 | 2.9 |
| Breast | 4 | 1.1 |
| Type of metastasis | ||
| Visceral | 212 | 55.9 |
| Non-visceral | 167 | 44.1 |
| Adjuvant or neo-adjuvant chemotherapy | ||
| Yes | 341 | 90.0 |
| Anthracyclines only | 106 | 28.0 |
| Taxanes only | 24 | 6.3 |
| Both Anthracyclines and Taxanes | 192 | 50.7 |
| With Platinum | 36 | 9.5 |
| Without Platinum | 305 | 80.5 |
| No | 38 | 10.0 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group